Confirm the diagnosis with current clinical and genetic criteria
The 2021 International TSC Consensus Group reaffirmed both clinical and genetic diagnostic criteria. Molecular testing for TSC1 and TSC2 can confirm the diagnosis, clarify familial risk and identify mosaic disease, but a negative standard blood test does not automatically exclude clinically definite TSC because mosaic variants can be difficult to detect. Genetic results should therefore be interpreted together with the phenotype.
TSC is multisystem, so the active problem should define the referral
Brain, kidneys, lungs, heart, skin, eyes and neuropsychiatric function can be affected to very different degrees. A German center should first identify the current priority: uncontrolled seizures, a growing SEGA, renal angiomyolipoma, pulmonary disease, neurodevelopmental concerns or another manifestation. This avoids fragmented appointments that do not answer the main clinical question.
Epilepsy requires early and specialist assessment
Seizures are common in TSC and may begin in infancy. The international consensus places strong emphasis on early EEG surveillance in young children and rapid treatment of emerging epilepsy. Older children and adults with drug-resistant seizures may require video-EEG, high-resolution MRI, medication review, ketogenic therapy, neurostimulation or epilepsy-surgery evaluation depending on seizure type and localization.
Brain MRI surveillance focuses on SEGA and other structural manifestations
Cortical tubers, subependymal nodules and SEGA are characteristic cerebral manifestations. Serial MRI is used to identify a growing SEGA before obstructive hydrocephalus or neurological deterioration develops. A changing lesion should be reviewed by an experienced TSC team to determine whether surveillance, neurosurgery or systemic mTOR-inhibitor therapy is more appropriate.
SEGA can be treated surgically or with mTOR inhibition depending on the case
Surgery remains an important option for a resectable symptomatic or growing SEGA, especially when hydrocephalus or mass effect requires urgent control. Everolimus is authorized in the EU for TSC-associated SEGA requiring therapeutic intervention when surgery is not appropriate. Treatment choice depends on anatomy, urgency, prior surgery, age, other TSC manifestations and the practical burden of long-term drug monitoring.
Renal angiomyolipoma is a major adult TSC risk outside neurology
Kidney surveillance is essential because angiomyolipomas can enlarge, bleed or impair renal function. The EMA authorizes everolimus for selected adults with TSC-associated renal angiomyolipoma at risk of complications who do not require immediate surgery. Interventional radiology, nephrology and urology may be needed for aneurysms, bleeding risk or complex renal disease.
mTOR therapy is indication-specific rather than universal TSC treatment
Everolimus targets the dysregulated mTOR pathway in TSC and has established EU indications for selected SEGA, renal angiomyolipoma and refractory focal seizures. It is not a generic treatment for every manifestation or every patient. Specialist selection requires review of expected benefit, infection risk, mouth ulcers, metabolic effects, drug interactions, vaccination status, laboratory monitoring and the need for therapeutic-drug monitoring in some indications.
TAND screening belongs in routine TSC care
TSC-associated neuropsychiatric disorders (TAND) can include attention, autism-spectrum features, intellectual disability, learning difficulties, anxiety, mood symptoms, sleep problems and behavioral concerns. These may be more disabling than tumor burden. A multidisciplinary pathway should actively screen for TAND and connect patients with neuropsychology, psychiatry, developmental pediatrics, school support or rehabilitation when appropriate.
Adults need continued surveillance after pediatric care ends
TSC does not become a purely neurological disorder in adulthood. Renal angiomyolipoma, pulmonary lymphangioleiomyomatosis in women, epilepsy, SEGA follow-up in selected patients, hypertension, skin disease and neuropsychiatric needs can persist or emerge later. Transition from pediatric to adult multidisciplinary care should therefore be planned rather than allowing surveillance to stop after adolescence.
Charité, UKE and Freiburg provide complementary verified TSC pathways
Charité operates a certified TSC Center Berlin-Brandenburg with an adult special clinic coordinating more than ten specialties. UKE publishes a certified pediatric TSC center within neuropediatrics and genetic-neurology care. University Medical Center Freiburg lists TSC among the rare and complex epilepsies managed by its comprehensive epilepsy center, including advanced diagnostics, neurostimulation and epilepsy surgery when indicated.
What to send for a German TSC second opinion
A useful review should show the multisystem phenotype and the exact unresolved question.
- TSC1/TSC2 genetic report, including testing method and variant classification
- Neurology and clinical-genetics summaries
- Brain MRI DICOM files and serial radiology reports
- EEG/video-EEG reports and seizure diary
- Current and previous antiseizure medicines with response and adverse effects
- SEGA measurements and prior neurosurgical reports if relevant
- Renal MRI/ultrasound reports and kidney-function results
- Pulmonary CT/function reports when LAM is relevant
- Cardiology, dermatology and ophthalmology reports when involved
- Neuropsychology/developmental/TAND assessments
- Current or prior everolimus/sirolimus treatment with dose, monitoring and response
- Exact question: diagnosis confirmation, epilepsy review, SEGA treatment, mTOR eligibility, renal-risk review or multidisciplinary surveillance plan
Urgent neurological or bleeding symptoms should be assessed locally
Prolonged seizures, rapidly worsening neurological deficit, severe headache with vomiting or reduced consciousness, suspected hydrocephalus, acute flank pain with suspected renal bleeding or respiratory deterioration require urgent local evaluation. Planned medical travel should not delay emergency treatment.
Official sources
Sources last checked 2026-09-03. Clinical pathways, eligibility and hospital procedures can change; confirm current requirements directly with the treating center.
- Charité special clinic for tuberous sclerosis — Charité – Universitätsmedizin Berlin ↗
- UKE pediatric neurology and certified TSC center — University Medical Center Hamburg-Eppendorf (UKE) ↗
- Freiburg Epilepsy Center — University Medical Center Freiburg ↗
- 2021 International TSC diagnostic, surveillance and management recommendations — International Tuberous Sclerosis Complex Consensus Group ↗
- Votubia (everolimus) EPAR — European Medicines Agency ↗